Accéder au contenu
MilliporeSigma

ATF4-Dependent NRF2 Transcriptional Regulation Promotes Antioxidant Protection during Endoplasmic Reticulum Stress.

Cancers (2020-03-04)
Carmen Sarcinelli, Helena Dragic, Marie Piecyk, Virginie Barbet, Cédric Duret, Audrey Barthelaix, Carole Ferraro-Peyret, Joelle Fauvre, Toufic Renno, Cédric Chaveroux, Serge N Manié
RÉSUMÉ

Endoplasmic reticulum (ER) stress generates reactive oxygen species (ROS) that induce apoptosis if left unabated. To limit oxidative insults, the ER stress PKR-like endoplasmic reticulum Kinase (PERK) has been reported to phosphorylate and activate nuclear factor erythroid 2-related factor 2 (NRF2). Here, we uncover an alternative mechanism for PERK-mediated NRF2 regulation in human cells that does not require direct phosphorylation. We show that the activation of the PERK pathway rapidly stimulates the expression of NRF2 through activating transcription factor 4 (ATF4). In addition, NRF2 activation is late and largely driven by reactive oxygen species (ROS) generated during late protein synthesis recovery, contributing to protecting against cell death. Thus, PERK-mediated NRF2 activation encompasses a PERK-ATF4-dependent control of NRF2 expression that contributes to the NRF2 protective response engaged during ER stress-induced ROS production.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Peroxyde d'hydrogène (30 %), (Perhydrol) for analysis EMSURE ISO
Sigma-Aldrich
Puromycine dihydrochloride, Ready Made Solution, from Streptomyces alboniger, 10 mg/mL in H2O, suitable for cell culture
Sigma-Aldrich
Tunicamycine from Streptomyces sp.
Sigma-Aldrich
Anticorps anti-puromycine, clone 12D10, clone 12D10, from mouse
Sigma-Aldrich
Thapsigargine, ≥98% (HPLC), solid film
SAFC
Milieu de Eagle modifié par Dulbecco (DMEM)/Mélange nutritif F-12 de Ham, With 15 mM HEPES, without L-glutamine, L-leucine, L-lysine, L-methionine, CaCl2, MgCl2, MgSO4, sodium bicarbonate, and phenol red, powder, suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human ATF4